par Davies, C;Godwin, J;Gray, Richard;Clarke, M.J.;Cutter, D;Darby, S;McGale, P;Pan, Huade;Taylor, C;Wang, Yiwei ;Dowsett, Mitch;Ingle, James N;Peto, R
Référence Lancet, 378, 9793, page (771-784)
Publication Publié, 2011-08
Référence Lancet, 378, 9793, page (771-784)
Publication Publié, 2011-08
Article révisé par les pairs
Résumé : | As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen. |